Crown Bioscience Brings Top Scientists Together

Crown Bioscience hosted a symposium earlier this month for some of the industry’s leading experts to discuss the latest scientific discoveries in translational oncology.

“Some of the foremost researchers in this field shared information about immuno-oncology therapies and their impact on translational oncology,” said Christopher Murriel, Ph.D., who chaired the event in San Diego. A senior scientist in department of cancer biology at OncoMed Pharmaceuticals, he spoke at the symposium about the use of patient-derived and murine tumor models to predict impacts on cancer stem cells and anti-tumor immunity.

“Translational research, particularly in oncology, holds tremendous potential toward therapeutic drug development and clinical advancement - and the scientists at this symposium presented exciting research that demonstrates how much opportunity exists,” said Murriel. Using clinically-relevant models, Crown Bioscience helps researchers make the best decisions to speed the optimum drug candidates to clinical development.

“We’re pleased to share our expertise and sponsor this forum for scientists and clinicians to discuss the merits of current and future approaches,” said Jean-Pierre Wery, Ph.D., resident of Crown Bioscience. “Our goal is to spur change by helping the industry translate preclinical research into medicines to improve the health and quality of life of patients.”

Henry Li, Ph.D., vice president of translational oncology at Crown Bioscience, discussed the molecular pathway of patient-derived xenograft diseases. Tommy Broudy, Ph.D., general manager and chief scientific officer at Crown Bioscience San Diego, spoke about the adoption of clinically relevant models in oncology therapeutics.

Chief scientists from Decoy Biosystems, Tragara Pharmaceuticals, ImmunGene, Regulus Therapeutics, Ignyta and Pfizer also spoke.

Crown Bioscience will host another symposium Nov. 4 in Boston; details will soon be provided.